Objective:
To explore how the cell and gene therapy sector can rethink value, access, and affordability as therapies transition from clinical trials to routine care.
Approach:
- Discussion: Industry leaders share insights on the challenges and potential solutions regarding access to cell and gene therapies.
Key Findings:
- High manufacturing costs and complex delivery pathways restrict patient access to cell and gene therapies.
- Uncertain reimbursement models pose additional barriers to access.
- Reducing production costs and treating patients earlier could enhance accessibility.
- Expanding delivery beyond specialist centers is necessary for broader access.
- Long-term value assessment of therapies is crucial, rather than focusing solely on upfront costs.
Interpretation:
Collaboration among manufacturers, regulators, healthcare systems, payers, and patient advocates is essential for improving access to cell and gene therapies.
Limitations:
- The discussion does not provide specific strategies or frameworks for implementation.
- Insights are based on perspectives from industry leaders without empirical data.
Conclusion:
Addressing the challenges of value, access, and affordability in cell and gene therapy requires a multifaceted approach involving various stakeholders.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
